Back to Press Releases

PanOxyl® BPO Acne Treatment Bar Wins Coveted Allure Best of Beauty Award

PanOxylAcneTreatmentBar_2025AllureAward_Opt2.jpg

NASHVILLE, Tenn., September 16, 2025 /PRNewswire/ -- Crown Laboratories, Inc., a Revance company, is proud to announce that its therapeutic skincare brand, PanOxyl®, has been awarded the prestigious 2025 Allure Best of Beauty Award for its Acne Treatment Bar 10% Benzoyl Peroxide. This marks the first time the product has received this honor, underscoring its efficacy and innovative format within the acne care category.

For more than 25 years, the Allure Best of Beauty Awards have set the gold standard in the industry, spotlighting products that deliver on their promises through rigorous testing and expert evaluation. PanOxyl’s dermatologist-backed Acne Treatment Bar stood out for its potent formula and convenient solid-bar format, designed to effectively treat acne on the face, chest, and back.

“Receiving an Allure Best of Beauty Award is one of the highest accolades in beauty,” said Nicole Watson, Senior Vice President, Therapeutics Marketing. “We’re honored to see the Acne Treatment Bar recognized this year for its ability to deliver real results and help people feel more confident in their skin.”

For more than 25 years, the Allure Best of Beauty Awards have set the gold standard in the industry, spotlighting products that deliver on their promises through rigorous testing and expert evaluation. PanOxyl’s dermatologist-backed Acne Treatment Bar stood out for its potent formula and convenient solid-bar format, designed to effectively treat acne on the face, chest, and back.

“Receiving an Allure Best of Beauty Award is one of the highest accolades in beauty,” said Nicole Watson, Senior Vice President, Therapeutics Marketing. “We’re honored to see the Acne Treatment Bar recognized this year for its ability to deliver real results and help people feel more confident in their skin.”

Formulated with 10% benzoyl peroxide, the maximum strength available without a prescription, PanOxyl’s Acne Treatment Bar works to eliminate acne-causing bacteria, clear blackheads, whiteheads, and pimples, and help prevent new breakouts. The formula is vegan, soap-free, pH-balanced, and free of added fragrances or dyes, making it suitable for acne-prone skin. Its solid-bar format offers a convenient, multi-purpose solution, perfect for at home or on the go.

The PanOxyl BPO Acne Treatment Bar is available nationwide at major retailers and online. For more information, please visit www.PanOxyl.com.

About PanOxyl
Known for its #1 selling dermatologist-recommended acne products in the U.S., PanOxyl offers a full line of acne-prone skin care products designed to cleanse, manage, and moisturize to reveal your best-looking skin. Always backed by science, PanOxyl has been used and trusted by millions around the world for the last 50 years. For more information about PanOxyl or its products, visit www.panoxyl.com.

About Revance
Revance is a fast-growing, highly acquisitive, global aesthetics and skincare company committed to delivering innovative aesthetics and market-leading skincare solutions across every stage of life. With a differentiated portfolio and market position, Revance meets the evolving needs of patients and consumers worldwide through continued innovation and the commercialization of new products and treatments. Focused on skin science for life, Revance continues to expand its global footprint, with distribution spanning 60 countries and a significant opportunity to enter new markets.
Revance’s balanced portfolio includes innovative products in the aesthetics space such as DAXXIFY® (DaxibotulinumtoxinA-lanm) for injection, the RHA® Collection of dermal fillers by Teoxane SA, and SkinPen®, an industry-leading microneedling device. RHA® technology is proprietary to and manufactured in Switzerland by Teoxane SA, and Revance is an independent distributor of Teoxane SA to supply the RHA Collection of dermal fillers to the U.S. market. In addition, its consumer skincare portfolio includes leading brands such as PanOxyl®, Blue Lizard®, StriVectin® and BIOJUVE®.

RHA® is a trademark of TEOXANE SA.

Learn more at Revance.com, RevanceAesthetics.com, CrownLaboratories.com, and CrownAesthetics.com. Please see DAXXIFY® full Prescribing Information, including Boxed Warning and Medication Guide.

Contact:
Jill McGonigle
978-866-4931
jmcgonigle@crownlaboratories.com

IMPORTANT SAFETY INFORMATION for DAXXIFY® (daxibotulinumtoxinA-Ianm) for injection

Indications

(daxibotulinumtoxinA-lanm) injection is an acetylcholine release inhibitor and neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients and for the treatment of cervical dystonia in adults.

WARNING: DISTANT SPREAD OF TOXIN EFFECT The effects of DAXXIFY® and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. DAXXIFY® is not approved for the treatment of spasticity or any conditions other than cervical dystonia and glabellar lines.

IMPORTANT SAFETY INFORMATION

Contraindications

DAXXIFY® contraindications include hypersensitivity to any botulinum toxin preparation or any of the components in the formulation and infection at the injection site(s).

Warnings and Precautions

Please refer to Boxed Warning for Distant Spread of Toxin Effect.

The potency Units of DAXXIFY® are not interchangeable with other preparations of other botulinum toxin products. Recommended dose and frequency of administration should not be exceeded. Patients should seek immediate medical attention if respiratory, speech or swallowing difficulties occur. Use caution when administering to patients with pre-existing cardiovascular disease. Concomitant neuromuscular disorders may exacerbate clinical effects of treatment.

Adverse Reactions

The most commonly observed adverse reactions are:

Glabellar lines (≥1%) were headache (6%), eyelid ptosis (2%) and facial paresis (1%).

Cervical Dystonia (≥5%): headache (9%), injection site pain (8%), injection site erythema (6%), muscular weakness (5%), and upper respiratory tract infection (5%).

Drug Interactions

Co-administration of DAXXIFY® and aminoglycoside antibiotics, anticholinergic agents or any other agents interfering with neuromuscular transmission or muscle relaxants should only be performed with caution as the effect of DAXXIFY® may be potentiated. The effect of administering different botulinum neurotoxins during course of treatment with DAXXIFY® is unknown.

Use in Specific Populations

DAXXIFY® is not recommended for use in children or pregnant women.

Please see DAXXIFY® full Prescribing Information, including Boxed Warning and Medication Guide.

To report side effects associated with DAXXIFY®, please visit safety.revance.com, or call 1-877-373-8669. You may also report side effects to the FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch

DAXI-004726

Facebook Instagram Twitter LinkedIn

FOR CUSTOMER SERVICE, PRODUCT INFORMATION, NEW ACCOUNTS OR ADVERSE EVENTS CALL: 877-3REV-NOW

1222 DEMONBREUN ST

20TH FLOOR

NASHVILLE, TN 37203

©2025 REVANCE.
RHA® and RHA Redensity® are registered trademarks of TEOXANE SA, manufactured in Switzerland. The TEOXANE RHA® Collection is exclusively distributed by Revance®. All other trademarks are the property of their respective owners.
CORP-00147

SOCIAL MEDIA COMMUNITY GUIDELINES PRIVACY POLICY TERMS OF USE
WARNING: DISTANT SPREAD OF TOXIN EFFECT The effects of DAXXIFY® and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. DAXXIFY® is not approved for the treatment of spasticity or any conditions other than cervical dystonia and glabellar lines.